# Eli Lilly beats Novo Nordisk to China approval for first oral GLP-1 weight-loss drug

https://mins.news/en/item/141591

- South China Morning Post, 2026-11-13 01:01 UTC
- Health
- Original: https://www.scmp.com/business/companies/article/3374229/eli-lilly-beats-novo-nordisk-china-approval-first-oral-glp-1-weight-loss-drug

> China approved Eli Lilly’s weight-loss pill orforglipron, making it the country’s first available oral GLP-1 treatment for obesity. The National Medical Products Administration said Thursday that the once-daily drug, sold as Foundayo, can be used for chronic weight management by obese or overweight adults.

## Related coverage

- [China approves Eli Lilly weight-loss pill orforglipron](https://mins.news/en/item/140188) — Reuters, 2026-11-12